Royal Bank Of Canada reaffirmed their underperform rating on shares of Pfizer (NYSE:PFE – Free Report) in a research report report published on Monday,Benzinga reports. They currently have a $25.00 target price on the biopharmaceutical company’s stock.
A number of other research analysts also recently commented on PFE. Guggenheim upped their price objective on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Daiwa Securities Group downgraded shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective for the company. in a research note on Thursday, February 12th. HSBC upped their price objective on shares of Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. Zacks Research raised shares of Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $28.45.
Pfizer Stock Down 0.1%
Pfizer (NYSE:PFE – Get Free Report) last released its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. Pfizer’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.63 EPS. As a group, sell-side analysts expect that Pfizer will post 2.98 EPS for the current year.
Institutional Trading of Pfizer
A number of institutional investors and hedge funds have recently bought and sold shares of PFE. Norges Bank acquired a new stake in Pfizer during the 4th quarter worth approximately $1,830,986,000. Morgan Stanley increased its position in Pfizer by 19.2% during the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after purchasing an additional 14,342,946 shares in the last quarter. Bank of New York Mellon Corp increased its position in Pfizer by 38.9% during the 4th quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company’s stock worth $1,208,023,000 after purchasing an additional 13,581,757 shares in the last quarter. Franklin Resources Inc. increased its position in Pfizer by 47.8% during the 3rd quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock worth $638,787,000 after purchasing an additional 8,108,887 shares in the last quarter. Finally, Janus Henderson Group PLC increased its position in Pfizer by 577.5% during the 4th quarter. Janus Henderson Group PLC now owns 8,786,084 shares of the biopharmaceutical company’s stock worth $218,817,000 after purchasing an additional 7,489,189 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.
Key Headlines Impacting Pfizer
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: CICC initiated coverage of Pfizer with an Outperform rating and a $33 price target, signaling institutional upside expectations versus current levels. CICC Initiates Coverage of Pfizer Inc. (PFE) With an Outperform Rating
- Positive Sentiment: The FDA accepted for Priority Review a sBLA for PADCEV + Keytruda as a perioperative treatment for muscle‑invasive bladder cancer — if approved this could become a new standard of care and expand Pfizer’s oncology revenue stream. U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
- Neutral Sentiment: Pfizer is listed among 22 companies expanding in Hong Kong — a sign of geographic growth intent but unlikely to drive near‑term earnings surprises. Pfizer, Amgen among 22 firms to expand in Hong Kong: SCMP
- Neutral Sentiment: Andrew Baum, Pfizer’s Chief Strategy and Innovation Officer, is transitioning to a new role and will eventually leave as part of a strategic simplification — this could mean organizational refocus but also creates short‑term execution uncertainty. Pfizer’s Strategy and Innovation Officer Andrew Baum to leave drugmaker, analyst note says
- Negative Sentiment: Royal Bank of Canada reiterated an “underperform” rating and a $25 price target, implying downside vs. recent levels and pressuring sentiment among value/defensive investors. RBC Reaffirms Underperform on Pfizer
About Pfizer
Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
See Also
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
